Loading
HER2/EGFR in Cancer Research · Journal article
Jnci Journal of the National Cancer Institute · August 8, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical mechanistic study testing whether inhibitors of apoptosis proteins (IAP/XIAP antagonists) enhance the in vitro and in vivo activity of sacituzumab govitecan in breast cancer models. The work identifies a potential rational combination strategy but provides no clinical evidence, efficacy in patients, or phase 1+ trial data.
Preclinical in vitro and in vivo (patient-derived xenograft) combination study. Breast cancer cell lines and patient-derived xenografts (PDXs); no human subjects.. Intervention: Sacituzumab govitecan combined with IAP inhibitors (birinapant or tolinapant). Compared with: Sacituzumab govitecan alone.
IAP antagonists (birinapant, tolinapant) combined with SG showed greater antitumor activity in PDX models compared with SG alone. SG combined with birinapant or tolinapant significantly prolonged event-free survival versus SG alone in PDX experiments. In vitro, IAP antagonists synergized with SG in inhibition of cell viability, colony formation, and induction of apoptosis.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work suggests a rationale for clinical investigation of SG combined with IAP inhibitors in breast cancer. However, it is purely preclinical; clinical trials would be required to determine safety and efficacy in patients, and no such data are presented here.
Preclinical mechanistic study in cell lines and xenografts proposing a combination strategy; no clinical trial data, no human efficacy endpoints, and no regulatory or phase 1+ evidence to support practice change.
As stated by the source record.
Quoted from the source exactly as published.
This work suggests a rationale for clinical investigation of SG combined with IAP inhibitors in breast cancer. However, it is purely preclinical; clinical trials would be required to determine safety and efficacy in patients, and no such data are presented here.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
TROP2 antibody-drug conjugate sacituzumab govitecan (SG) is approved for treatment of advanced breast cancer. However, intrinsic and acquired resistance occur, leading to a need for novel therapies. We hypothesized that antagonists of inhibitor of apoptosis protein (IAP) enhance the activity of SG and its payload. In this preclinical study, we employed breast cancer models, including patient-derived xenografts (PDXs) and cell lines, to conduct combination therapies with SG and IAP inhibitors. In PDXs, birinapant enhanced the antitumor activity of several chemotherapeutics, especially irinotecan, a metabolic precursor of payload SN-38. We subsequently demonstrated that combinations of SG with birinapant or tolinapant had greater antitumor activity and significantly prolonged event-free survival compared with SG alone. In vitro, IAP antagonists significantly synergized with SG on inhibition of cell viability and colony formation, and on apoptosis induction. These findings suggest that SG combination with IAP inhibitors may represent an effective therapeutic strategy for breast cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.